<DOC>
	<DOCNO>NCT00691405</DOCNO>
	<brief_summary>A dose ranging study evaluate safety , tolerability efficacy arformoterol ( give twice day ) subject COPD .</brief_summary>
	<brief_title>A Dose Ranging Study Arformoterol Given Once Daily Compared Arformoterol Given Twice Daily Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This study double-blind , repeat-dose , randomize , multicenter , two-part , parallel-group , dose-ranging study arformoterol placebo treatment subject COPD . Approximately 215 subject randomize study . Study participation consist total eight ( 8 ) study visit approximately ten ( 10 ) week subject . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Subject may male female must age great equal 35 year day inform consent sign . Female subject less equal 65 year age must serum pregnancy test conduct study start confirm negative . Subjects childbearing potential must use acceptable method birth control agree continue use throughout study . In order consider childbearing potential female subject must : document surgically sterile ( defined status posthysterectomy bilateral tubal ligation ) OR postmenopausal Subject must primary diagnosis COPD , may include component chronic bronchitis and/or emphysema . Diagnosis make screen process . Subject must minimum smoke history 15 packyears ( packyears = number cigarette pack per day time number year ) . Subject must chest xray consistent diagnosis COPD ( e.g. , diagnostic pneumonia , infection , atelectasis , pneumothorax ) take less equal 6 month study start . If chest xray take less equal 6 month study start , chest xray perform Visit 1 . Subject must able complete study questionnaire log reliably . A female pregnant lactating . Subject participate investigational drug study within 30 day prior study start , currently participate another investigational drug study . Subject 's schedule travel prevents completion require visit . Subject schedule inpatient hospitalization , include elective surgery ( patient outpatient ) trial . Subject lifethreatening/unstable respiratory status , include upper low respiratory tract infection , within 30 day prior study start . Subject known history asthma ( except childhood asthma ) chronic respiratory disease ( include current history sleep apnea ) COPD ( chronic bronchitis and/or emphysema ) . Subject known history alpha 1 antitrypsin deficiencyrelated emphysema . Subject history cancer except nonmelanoma skin cancer . Subjects history cancer consider surgically cure without recurrence within past 5 year may participate study . History hematologic/lymphatic malignancy treat chemotherapy radiation allow , condition . Subject history lung resection one full lobe recipient lung major organ transplant . Subject require continuous supplemental oxygen therapy ( unless subject resides elevation great equal 4,000 foot ) . Subject change dose type medication COPD within 14 day screen visit . Subject know sensitivity arformoterol , ipratropium albuterol excipients contain formulation . Subject history substance abuse within 12 month Visit 1 , positive urine drug screen study start . Subject use prescription drug concomitant betaagonist administration contraindicate ( e.g. , betablockers ) . Subject significant blood loss ( &gt; 500 cc ) donate blood within 60 day precede screen plan donate blood within 60 day complete study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Arformoterol</keyword>
	<keyword>( R , R ) -formoterol</keyword>
</DOC>